AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South Korea
03 avr. 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), a world leader in cannabinoid research and development, today announced that it has...
Visualize Your Home With A TAMKO® Roof On HOVER®
09 janv. 2018 11h04 HE
|
TAMKO Building Products, Inc.
Orlando, Florida, Jan. 09, 2018 (GLOBE NEWSWIRE) -- TAMKO Building Products, Inc. is excited to announce that its roofing products are now options in HOVER®’s product library, a platform that...
Meritage Homes to Unveil Pioneering reNEWable Living Home in Orlando
08 janv. 2018 11h35 HE
|
Meritage Homes Corporation
PHOENIX, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE:MTH), a leading U.S. homebuilder, today announced the completion of the reNEWable Living Home. In connection with BSB...
Axim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)
21 nov. 2017 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results...
AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City
07 sept. 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
AXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency Study
19 juin 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company has...
AXIM Biotech Holds Annual Board Meeting
25 janv. 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 25, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, held its second annual board meeting on...
AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
18 janv. 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating...
AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum
04 janv. 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK)...
AXIM® Biotech Receives Medical Ethical Committee Approval to Begin IBS Trial for Canchew Plus® CBDGum
06 déc. 2016 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, Dec. 06, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it received...